Financials Pulike Biological Engineering, Inc.

Equities

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-04-29 EDT			5-day change	1st Jan Change
17.43 ^CNY	-.--%		-3.43%	-23.05%

04-25	Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-25	Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	6,083	6,541	6,954	9,468	7,838	5,912	-	-
Enterprise Value (EV) ¹	6,083	6,287	6,785	9,194	7,522	4,884	4,791	5,912
P/E ratio	55.6 x	28.8 x	28.3 x	50.7 x	45.3 x	28.7 x	21.6 x	18.9 x
Yield	1.06%	2.41%	0.9%	1.28%	1.77%	3.9%	3.68%	6.94%
Capitalization / Revenue	9.17 x	7.04 x	6.33 x	7.71 x	6.26 x	4.24 x	3.68 x	3.29 x
EV / Revenue	9.17 x	6.77 x	6.18 x	7.49 x	6 x	3.5 x	2.98 x	3.29 x
EV / EBITDA	38.7 x	21.1 x	19.7 x	35.8 x	26.4 x	15.1 x	11 x	11.7 x
EV / FCF	-	-	-65,277,182 x	-	-	-	-	-
FCF Yield	-	-	-0%	-	-	-	-	-
Price to Book	3.67 x	3.9 x	3.95 x	3.45 x	2.93 x	2.14 x	2 x	1.94 x
Nbr of stocks (in thousands)	321,496	315,539	314,642	346,062	346,062	339,208	-	-
Reference price ²	18.92	20.73	22.10	27.36	22.65	17.43	17.43	17.43
Announcement Date	20-04-28	21-03-08	22-04-28	23-04-25	24-04-25	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	663.2	928.5	1,099	1,228	1,253	1,394	1,608	1,797
EBITDA ¹	157.3	297.8	343.9	256.9	285.4	324.5	436.2	504.6
EBIT ¹	106.9	246.6	284.6	183.2	193	231.6	313.4	351.5
Operating Margin	16.12%	26.56%	25.91%	14.92%	15.41%	16.61%	19.49%	19.56%
Earnings before Tax (EBT) ¹	117.2	260	284.2	184	194.6	232.2	312.1	352.8
Net income ¹	109.2	227.7	244.1	174.1	174.5	209.6	280.1	318
Net margin	16.47%	24.53%	22.22%	14.18%	13.93%	15.04%	17.42%	17.7%
EPS ²	0.3400	0.7200	0.7800	0.5400	0.5000	0.6080	0.8052	0.9200
Free Cash Flow	-	-	-103.9	-	-	-	-	-
FCF margin	-	-	-9.46%	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	0.2000	0.5000	0.2000	0.3500	0.4000	0.6800	0.6415	1.210
Announcement Date	20-04-28	21-03-08	22-04-28	23-04-25	24-04-25	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	-	254	169	274	316	1,028	1,121	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-104	-	-	-	-	-
ROE (net income / shareholders' equity)	6.68%	13.9%	14.1%	8.42%	6.31%	7.5%	9.34%	10.2%
ROA (Net income/ Total Assets)	5.74%	11.6%	11.6%	-	-	6.16%	7.54%	8.62%
Assets ¹	1,904	1,967	2,099	-	-	3,404	3,717	3,691
Book Value Per Share ²	5.160	5.320	5.600	7.930	7.720	8.140	8.710	9.000
Cash Flow per Share ²	0.4400	0.8100	0.6600	0.6600	0.8000	0.8200	1.090	1.120
Capex ¹	85.1	176	316	356	305	243	230	125
Capex / Sales	12.83%	18.98%	28.81%	29.02%	24.31%	17.4%	14.29%	6.94%
Announcement Date	20-04-28	21-03-08	22-04-28	23-04-25	24-04-25	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.43 CNY

Average target price

20.24 CNY

Spread / Average Target

+16.09%

	1st Jan change	Capi.
PULIKE BIOLOGICAL ENGINEERING, INC.	-23.05%	817M
ELANCO ANIMAL HEALTH INCORPORATED	-10.10%	6.48B
BLUESTAR ADISSEO COMPANY	+24.75%	3.7B
VIRBAC	-3.20%	3.1B
VIMIAN GROUP AB	+2.53%	1.44B
JINYU BIO-TECHNOLOGY CO., LTD.	-15.13%	1.37B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-25.63%	1.24B
VETOQUINOL SA	-6.64%	1.19B
WUHAN KEQIAN BIOLOGY CO.,LTD	-10.84%	1.17B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-.--%	1.05B